Purchase Summary

In order to access content on the FENIX Marketplace, you must have an account. You will also have access to FENIX Free updates.

The price for access is $599.00.

Account Information Already have an account? Log in here

Username

Password

Confirm Password

Work E-mail Address

Confirm E-mail Address

Occupation

Other

Full Name LEAVE THIS BLANK

Payment Information We accept all major credit cards

Card Number

Expiration Date

CVC

I want to receive updates from fenix.group.

By selecting this, I agree to receive emails from fenix.group.

Processing...

You will be redirected to view the full article after purchasing. You will receive your account and payment information in a confirmation email, and can be viewed at any time in your Account.

RETURN TO HOME

$599

Insulin Delivery

March 26, 2019

Cellnovo to Close Operations?

Here is a brief preview of this blast: Cellnovo announced that it does not have sufficient capital to support a broader launch of its Gen 3 tubed patch pump which is negatively impacting the company's overall operations. According to the press release, Cellnovo "[intends] to continue contacts initiated with strategic partners and investors in order to protect the value of the assets." Given the financial situation, Cellnovo initiated collective proceedings in the UK and conciliation proceedings in France. Below, FENIX provides thoughts on Cellnovo's market position and the potential closure of its operations.

About The Author

Matthew Maryniak

President of Fenix Group International

Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.